Coya Therapeutics Inc (COYA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.81-8.77%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · COYA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“Enrollment in the ALSTARS Phase 2 ALS trial is proceeding as planned, and we remain on track to complete enrollment this year and report topline data in the first quarter of 2027.
Stated in 2 of 2 supplied quarters. Management reported: ““Enrollment in the ALSTARS Phase 2 ALS trial is proceeding as planned, and we remain on track to complete enrollment this year and report topline data in the first quarter of 2027.” “Upcoming Expected Milestones 2026: • 2H 2026: Complete enrollment in the ALSTARS Phase 2 trial.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
““Enrollment in the ALSTARS Phase 2 ALS trial is proceeding as planned, and we remain on track to complete enrollment this year and report topline data in the first quarter of 2027.”
““The ALSTARS trial is now in full recruitment mode, and we maintain our guidance for a 1Q 2027 topline readout.”
Financial Results As of June 30, 2026, Coya had cash and cash equivalents of $43.2 million, sufficient to fund operations, as currently planned, past the Phase 2 ALSTARS topline data readout and into…
Stated in 2 of 2 supplied quarters. Management reported: “Financial Results As of June 30, 2026, Coya had cash and cash equivalents of $43.2 million, sufficient to fund operations, as currently planned, past the Phase 2 ALSTARS topline data readout and into the second half of 2027.” “Financial Results As of March 31, 2026, Coya had cash and cash equivalents of $50.7 million.”
“Financial Results As of June 30, 2026, Coya had cash and cash equivalents of $43.2 million, sufficient to fund operations, as currently planned, past the Phase 2 ALSTARS topline data readout and into…”
“Financial Results As of March 31, 2026, Coya had cash and cash equivalents of $50.7 million.”
At the same time, we plan to initiate a Phase 2 study of COYA 302 in frontotemporal dementia (FTD) in the coming months.
Stated in 2 of 2 supplied quarters. Management reported: “At the same time, we plan to initiate a Phase 2 study of COYA 302 in frontotemporal dementia (FTD) in the coming months.” “• 2H 2026: Initiate Phase 2a study evaluating COYA 302 for the treatment of FTD.”
“At the same time, we plan to initiate a Phase 2 study of COYA 302 in frontotemporal dementia (FTD) in the coming months.”
“• 2H 2026: Initiate Phase 2a study evaluating COYA 302 for the treatment of FTD.”
Obtain FDA Fast Track designation, expand trial inclusion criteria, and publish scientific data supporting COYA 302's mechanism and clinical potential.
Appoint experienced independent director to support transition from clinical to commercial stage.
Over the trailing year it converted 0.50x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.